Savara Inc. (SVRA)
| Market Cap | 269.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.16M |
| Shares Out | 114.04M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 371,095 |
| Open | 2.30 |
| Previous Close | 2.37 |
| Day's Range | 2.27 - 2.40 |
| 52-Week Range | 1.02 - 2.82 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 4.08 (+72.88%) |
| Earnings Date | Mar 28, 2023 |
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for SVRA stock is "Buy." The 12-month stock price forecast is $4.08, which is an increase of 72.88% from the latest price.
News
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new...
Savara Reports Third Quarter 2022 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending S...
Savara to Participate in Three Upcoming Investor Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate a...
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new...
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2...
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will...
Savara Announces Resignation of Chief Medical Officer
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has res...
Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the UK's Medicines and Healthcare Prod...
Savara Reports Second Quarter 2022 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending Ju...
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poste...
3 Top Breakout Stocks to Add to Your Portfolio Now
Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.
Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an Innovation...
Savara to Present at Jefferies Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...
After Golden Cross, Savara Inc. (SVRA)'s Technical Outlook is Bright
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Savara to Present at H.C. Wainwright Global Investment Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...
Savara Reports First Quarter 2022 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending Mar...
Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it entered into a term loan agreement ...
Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a busi...
Savara to Present at Oppenheimer's 32nd Annual Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Op...
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...
Savara to Participate in Two Upcoming Investor Healthcare Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...
Savara Reports Third Quarter 2021 Financial Results and Provides Business Update
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter endi...
Savara to Present at the Jefferies London Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...
Savara to Present at the Inaugural Piper Sandler Lung Day
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate i...
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new e...